

Sylwia Chocholska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4790151/publications.pdf>

Version: 2024-02-01

44
papers

667
citations

567144

15
h-index

610775

24
g-index

47
all docs

47
docs citations

47
times ranked

1326
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. <i>Cells</i> , 2022, 11, 752.	1.8	4
2	Prognostic significance of isochromosome 17q in hematologic malignancies. <i>Oncotarget</i> , 2021, 12, 708-718.	0.8	3
3	Prognostic Value of Tie2-Expressing Monocytes in Chronic Lymphocytic Leukemia Patients. <i>Cancers</i> , 2021, 13, 2817.	1.7	3
4	Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review. <i>Annals of Agricultural and Environmental Medicine</i> , 2021, 29, 103-109.	0.5	0
5	The Relationship of ABCB1/MDR1 and CYP1A1 Variants with the Risk of Disease Development and Shortening of Overall Survival in Patients with Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 5276.	1.0	2
6	Association of Common Variants of TNFSF13 and TNFRSF13B Genes with CLL Risk and Clinical Picture, as Well as Expression of Their Products – APRIL and TACI Molecules. <i>Cancers</i> , 2020, 12, 2873.	1.7	4
7	High M-MDSC Percentage as a Negative Prognostic Factor in Chronic Lymphocytic Leukaemia. <i>Cancers</i> , 2020, 12, 2614.	1.7	16
8	The Impact of the <i>NOD2/CARD15</i> Variant (3020insC) and <i>PSMA6</i> Polymorphism (-8C>G) on the Development and Outcome of Multiple Myeloma. <i>BioMed Research International</i> , 2020, 2020, 1-15.	0.9	9
9	The Association of GSTT1, GSTM1, and TNF- β Polymorphisms With the Risk and Outcome in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2019, 9, 1056.	1.3	20
10	<p>>Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients</p><p></p>	0.9	6
11	Polymorphisms in the promoter region of the <i>CRBN</i> gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. <i>British Journal of Haematology</i> , 2019, 186, 695-705.	1.2	7
12	ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma. <i>Frontiers in Oncology</i> , 2019, 9, 44.	1.3	24
13	Intracellular IL-4 and IFN- γ expression in iNKT cells from patients with chronic lymphocytic leukemia. <i>Oncology Letters</i> , 2018, 15, 1580-1590.	0.8	12
14	Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 1683-1689.	0.6	4
15	Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease. <i>Oncotarget</i> , 2018, 9, 19136-19146.	0.8	5
16	Polymorphisms in the promoter region of the <i>CRBN</i> gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. <i>Oncotarget</i> , 2018, 9, 24054-24068.	0.8	6
17	TP53 polymorphism in plasma cell myeloma. <i>Folia Histochemica Et Cytobiologica</i> , 2018, 55, 203-211.	0.6	3
18	Skuteczne leczenie ibrutynibem chorego na przewlekłą... białaczkę... limfocytową... z obecnością... delecji 17p, opis przypadku. <i>Acta Haematologica Polonica</i> , 2018, 49, 251-256.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. <i>Leukemia and Lymphoma</i> , 2017, 58, 2089-2100.	0.6	12
20	Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number. <i>Oncotarget</i> , 2017, 8, 34661-34669.	0.8	28
21	Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2016, 95, 425-435.	0.8	7
22	Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 32846-32853.	0.8	44
23	The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2908-2913.	0.6	18
24	Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia. <i>Acta Haematologica</i> , 2015, 134, 255-262.	0.7	38
25	Thalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor. <i>Pharmacological Reports</i> , 2015, 67, 1193-1200.	1.5	3
26	The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1121-1127.	0.8	2
27	Cytotoxic Activity of Valproic Acid on Primary Chronic Lymphocytic Leukemia Cells. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 55-62.	0.6	6
28	CD1d expression is higher in chronic lymphocytic leukemia patients with unfavorable prognosis. <i>Leukemia Research</i> , 2014, 38, 435-442.	0.4	25
29	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. <i>Hematological Oncology</i> , 2013, 31, 41-48.	0.8	39
30	Intracellular cytokine expression in T cells from patients with chronic lymphocytic leukemia. <i>Acta Haematologica Polonica</i> , 2013, 44, 319-325.	0.1	0
31	Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity. <i>PLoS ONE</i> , 2013, 8, e78091.	1.1	47
32	Analysis of ex vivo Apoptosis of B and T cells from Peripheral Blood and Bone Marrow of Patients with Chronic Lymphocytic Leukemia. <i>Acta Haematologica Polonica</i> , 2012, 43, 336-341.	0.1	1
33	1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. <i>Leukemia and Lymphoma</i> , 2012, 53, 2500-2503.	0.6	10
34	Molecular Biology Methods in the Diagnosis of Multiple Myeloma. <i>Principles and Practice</i> , 2012, , 443-449.	0.3	5
35	Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2011, 90, 173-183.	0.8	35
36	Assessment of the pathway of apoptosis involving PAR-4, DAXX and ZIPK proteins in CLL patients and its relationship with the principal prognostic factors. <i>Folia Histochemica Et Cytobiologica</i> , 2011, 49, 98-103.	0.6	8

#	ARTICLE	IF	CITATIONS
37	JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients. <i>Folia Histochemica Et Cytobiologica</i> , 2011, 49, 267-271.	0.6	5
38	Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. <i>Annals of Hematology</i> , 2010, 89, 1115-1124.	0.8	30
39	Assessment of Peripheral Blood and Bone Marrow Cells Apoptosis Caused by Purine Analogues in Patients with Chronic Lymphocytic Leukemia in Correlation with Parameters of Disease Progression. <i>Acta Haematologica</i> , 2010, 123, 171-178.	0.7	2
40	BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: Correlation with biological and clinical features. <i>Leukemia Research</i> , 2009, 33, 1319-1327.	0.4	44
41	Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis. <i>Respiratory Medicine</i> , 2007, 101, 645-654.	1.3	17
42	The clinical significance of interleukin 18 assessment in sarcoidosis patients. <i>Respiratory Medicine</i> , 2007, 101, 722-728.	1.3	29
43	Molecular cytogenetic analysis of a familial interstitial deletion Xp22.2-22.3 with a highly variable phenotype in female carriers. <i>American Journal of Medical Genetics, Part A</i> , 2006, 140A, 604-610.	0.7	69
44	The Yield of Endobronchial Biopsy in Pulmonary Sarcoidosis: Connection between Spirometric Impairment and Lymphocyte Subpopulations in Bronchoalveolar Lavage Fluid. <i>Respiration</i> , 2004, 71, 72-76.	1.2	13